Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Page 1
MYC Induces Oncogenic Stress through RNA Decay and Ribonucleotide Catabolism in Breast Cancer.
Meena JK, Wang JH, Neill NJ, Keough D, Putluri N, Katsonis P, Koire AM, Lee H, Bowling EA, Tyagi S, Orellana M, Dominguez-Vidaña R, Li H, Eagle K, Danan C, Chung HC, Yang AD, Wu W, Kurley SJ, Ho BM, Zoeller JR, Olson CM, Meerbrey KL, Lichtarge O, Sreekumar A, Dacso CC, Guddat LW, Rejman D, Hocková D, Janeba Z, Simon LM, Lin CY, Pillon MC, Westbrook TF. Meena JK, et al. Cancer Discov. 2024 Sep 4;14(9):1699-1716. doi: 10.1158/2159-8290.CD-22-0649. Cancer Discov. 2024. PMID: 39193992 Free PMC article.
Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer.
Hillis AL, Martin TD, Manchester HE, Högström J, Zhang N, Lecky E, Kozlova N, Lee J, Persky NS, Root DE, Brown M, Cichowski K, Elledge SJ, Muranen T, Fruman DA, Barry ST, Clohessy JG, Madsen RR, Toker A. Hillis AL, et al. Cancer Res. 2024 Oct 1;84(19):3250-3266. doi: 10.1158/0008-5472.CAN-24-0970. Cancer Res. 2024. PMID: 39024548 Free PMC article.
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.
Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, Anurag M, Holt MV, Gou X, Pilcher JB, Goetz MP, Northfelt DW, Hilsenbeck SG, Marshall CG, Hyer ML, Papp R, Yin SY, De Angelis C, Schiff R, Fuqua SAW, Ma CX, Foulds CE, Ellis MJ. Chen A, et al. Mol Cancer Ther. 2024 Oct 1;23(10):1494-1510. doi: 10.1158/1535-7163.MCT-23-0564. Mol Cancer Ther. 2024. PMID: 38781103 Free PMC article.
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer.
Tai Y, Chow A, Han S, Coker C, Ma W, Gu Y, Estrada Navarro V, Kandpal M, Hibshoosh H, Kalinsky K, Manova-Todorova K, Safonov A, Walsh EM, Robson M, Norton L, Baer R, Merghoub T, Biswas AK, Acharyya S. Tai Y, et al. EMBO Mol Med. 2024 Aug;16(8):1957-1980. doi: 10.1038/s44321-024-00094-2. Epub 2024 Jul 2. EMBO Mol Med. 2024. PMID: 38956205 Free PMC article.
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms.
Pareja F, Dopeso H, Wang YK, Gazzo AM, Brown DN, Banerjee M, Selenica P, Bernhard JH, Derakhshan F, da Silva EM, Colon-Cartagena L, Basili T, Marra A, Sue J, Ye Q, Da Cruz Paula A, Yeni Yildirim S, Pei X, Safonov A, Green H, Gill KY, Zhu Y, Lee MCH, Godrich RA, Casson A, Weigelt B, Riaz N, Wen HY, Brogi E, Mandelker DL, Hanna MG, Kunz JD, Rothrock B, Chandarlapaty S, Kanan C, Oakley J, Klimstra DS, Fuchs TJ, Reis-Filho JS. Pareja F, et al. Cancer Res. 2024 Oct 15;84(20):3478-3489. doi: 10.1158/0008-5472.CAN-24-1322. Cancer Res. 2024. PMID: 39106449
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.
Stearns V, Jegede OA, Chang VT, Skaar TC, Berenberg JL, Nand R, Shafqat A, Jacobs NL, Luginbuhl W, Gilman P, Benson AB 3rd, Goodman JR, Buchschacher GL Jr, Henry NL, Loprinzi CL, Flynn PJ, Mitchell EP, Fisch MJ, Sparano JA, Wagner LI. Stearns V, et al. Clin Cancer Res. 2024 Jul 1;30(13):2709-2718. doi: 10.1158/1078-0432.CCR-23-2137. Clin Cancer Res. 2024. PMID: 38640040 Free PMC article.
12 results